Stem cell transplant using selected cells for myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 72 years old.
- Your MDS must be high-risk, as determined by a standard scoring system (IPSS-R score of 4.5 or higher), or you have MDS related to previous treatment or you need regular blood transfusions.
- You must have a suitable donor who is a full or nearly full match (8/8 or 7/8 match).
- You must be generally well enough to undergo a transplant, with a performance status of at least 70% on the Karnofsky scale.
- Your heart, liver, kidney, and lung function must meet minimum requirements.
- You must not have uncontrolled infections, HIV, or active hepatitis B or C.
- You must be willing to sign a consent form and participate in the study.
- You must not be pregnant or breastfeeding.
- You must not have significant heart disease or certain other active cancers unless disease-free for at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at using a family donor transplant right away for people with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this early transplant is safe and helps control the disease.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a machine that picks out healthy stem cells for a bone marrow transplant. It may help people with certain blood cancers or disorders get a transplant with fewer complications.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.